學術發表 

學術發表

jacky

1. Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM.  Liu CA, Harn HJ, Chen KP,  Lee JH, Lin SZ, Chiu TL. Journal of Oncology. 2022 ; Article ID 3236058; 14. doi: doi.org/10.1155/2022/3236058.

2. Biodegradable controlled-release polymer containing butylidenephthalide to treat a recurrent cervical spine glioblastoma with promising result: a compassionate trial report.  Pan YH, Lin SZ, Chiu TL. Anti-Cancer Drugs. 2022 ; 33(4). doi:  10.1097/CAD.0000000000001275.

3. Interstitial Control-Released Polymer Carrying a Targeting Small-Molecule Drug Reduces PD-L1 and MGMT Expression in Recurrent High-Grade Gliomas with TMZ Resistance. Liu CA, Liu WH, Ma HI, Chen YH, Hueng DY, Tsai WC, Lin SZ, Harn HJ, Chiou TW, Liu JW, Lee JH, Chiu TL.Cancers (Basel). 2022 Feb 18;14(4):1051. doi: 10.3390/cancers14041051.